Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL116634 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL188359 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL855471 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8067110 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL1958560 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL198686 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118731196-A | Qualitative and quantitative detection and analysis method and system for acyl carnitine and compound thereof | 复旦大学 | 2024-10-01 | — | — | CN | claimed |
| CN-113871008-B | Predictive model for early diagnosis of lung cancer and related products and application thereof | 大连医科大学附属第二医院 | 2024-09-10 | — | — | CN | claimed |
| US-20220118269-A1 | MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2022-04-21 | — | — | US | claimed |
| CN-113871008-A | Prediction model for early diagnosis of lung cancer and related products and application thereof | 大连医科大学附属第二医院 | 2021-12-31 | — | — | CN | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| US-12458617-B2 | Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3709817-B2 | COMPOSITIONS COMPRISING OMEGA-3 POLYUNSATURATED AND MEDIUM CHAIN FATTY ACIDS | HILLS PET NUTRITION INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313905-A1 | METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | disclosed |
| US-12424305-B2 | Closed-loop AI-optimized EMF treatment and digital delivery of data | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250216377-A1 | COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY | AGEX THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2012027533-A1 | SELECTABLE MARKERS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2401696-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT Life Sciences, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098865-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4963525-A | POLYPEPTIDES | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4847298-A | DOPA COMPOUNDS OR ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| US-4731360-A | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | FPR2, FPR1, FPR3 | MAPT 2558/4885MEN1 3045/4885KMT2A 4550/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | MAPT 1253/4885MEN1 4680/4885KMT2A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.